Strategy x Super Speed x Showdown -- New Competitive Puzzle Game “SHIKA-Q” to Launch Worldwide in Fall 2025
10.9.2025 07:00:00 EEST | Business Wire | Press release
AGNI-FLARE CO., LTD. (Headquarters: Yokohama, Kanagawa) today announced that its new online competitive puzzle game “SHIKA-Q” will be released worldwide (excluding certain regions) in Fall 2025 for Nintendo Switch, PlayStation®4, and PlayStation®5.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250828701219/en/
“SHIKA-Q” Game Title Logo
SHIKA-Q is an online, real-time puzzle battle played on a 10x10 board where players link blocks to launch rapid-fire attacks and defenses. At the core of the gameplay is music—not merely background sound, but original vocal tracks created to symbolize the battle, delivering an unprecedented sense of immersion.
Key Features
-
Strategy x Super Speed x Showdown.
Real-time puzzle battles where instant decisions determine victory, akin to a fighting game. -
Music at the Heart of Gameplay.
Each battle is driven by original vocal tracks, a core element of the experience. Character songs heighten tension and excitement in every match. -
Diverse Music Lineup.
- Challenge Mode (Single-player): 20 songs that evolve as players level up.
- Battle Pass: 10 additional character-inspired songs across 5 seasonal themes (Standard & Premium).
-
Characters & Worldbuilding.
A cast of unique characters awaits. Some will be revealed in the first announcement, with more details to follow. -
Online Play.
Includes Ranked Matches and a seasonal Battle Pass system, ensuring ongoing replayability.
The SHIKA-Q Development Team commented,“Thanks to our small, agile team, we achieved visual and musical dynamism never seen before. With SHIKA-Q, we aim to deliver a fusion of strategy and immersion—through music and gameplay—to players worldwide.”
Release Information
- Title: SHIKA-Q
- Genre: Competitive Puzzle Battle Game
- Platforms: Nintendo Switch / PlayStation®4 / PlayStation®5
- Release Date: Fall 2025 (planned)
- Price: To be announced
- Battle Pass: Standard / Premium (price and details to be announced)
-
Regions: Worldwide simultaneous release (excluding certain areas)
Please Note: The game will not release in China or Russia. In Taiwan, availability depends on the Nintendo eShop. Regional availability may also vary by platform status. - Format: Digital download only
Press Materials: https://drive.google.com/drive/folders/1ji--_0dcv9iTnd6gnQISXrT4XlpxhiGe
Company Profile
- AGNI-FLARE CO., LTD.
- CEO: Takeshi Inaba
- Head Office: Yokohama, Japan
- Business: Video game planning, development, and publishing
- Established: 2010
View source version on businesswire.com: https://www.businesswire.com/news/home/20250828701219/en/
Contacts
AGNI-FLARE PR
E-mail: info@shika-q.com
Official Website: https://shika-q.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fshika-q.com&es
heet=54314870&newsitemid=20250828701219&lan=en-US&anchor=https%3A%2F%2Fshika-q.c
om&index=2&md5=184a0d462e01ba8c88970ee2e9f48513
YouTube: https://youtube.com/@SHIKA-QOFFICIAL-z4m -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fyoutube.com%2F
%40SHIKA-QOFFICIAL-z4m&esheet=54314870&newsitemid=20250828701219&lan=en-US&ancho
r=https%3A%2F%2Fyoutube.com%2F%40SHIKA-QOFFICIAL-z4m&index=3&md5=3b4737dd165933c
06cdb2f99564e297e
Discord: https://discord.gg/wnZAxBqd4W -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdiscord.gg%2Fw
nZAxBqd4W&esheet=54314870&newsitemid=20250828701219&lan=en-US&anchor=https%3A%2F
%2Fdiscord.gg%2FwnZAxBqd4W&index=4&md5=896411249004b5e6fefba99014d50f3f
X: https://x.com/SHIKAQ_OFFICIAL -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2FSHIKAQ
_OFFICIAL&esheet=54314870&newsitemid=20250828701219&lan=en-US&anchor=https%3A%2F
%2Fx.com%2FSHIKAQ_OFFICIAL&index=5&md5=04358fe631d7d995496b38a7b07f80c8
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom